RECRUITING

A Clinical Study to Determine if Beta Glucan Reduces the Incidence, Duration or Severity of URTIs Among Skiers

Talk to us

Conditions

Upper Respiratory Tract InfectionsMental Stress

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is designed to determine if a dieatary supplement containing beta-glucan can reduce the incidence, severity and duration of upper respiratory tract infections among a group of highly trained athletes

Official Title

A Clinical Study to Determine if Beta-glucan Reduces the Incidence, Duration or Severity of Upper Respiratory Tract Infections Among Skiers

Quick Facts

Study Start:2023-03-06
Study Completion:2023-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05917015

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 30 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Provide informed consent by signing the electronic Information and Consent Form.
  2. * Male or females between the ages of 18 and 30 (inclusive) without regard to race or ethnic background
  3. * Are in generally good health and have no medical conditions that would prevent or interfere with their participation in the study
  4. * Are fully able and willing to comply with the requirements of the study
  5. * Are fully able and willing to keep scheduled appointments
  1. * Females that are pregnant, attempting to become pregnant or are currently lactating/nursing a child.
  2. * Individuals currently taking prescription medications that are known to be immunosuppressants (e.g. dexamethasone, tacrolimus, methotrexate)
  3. * Individuals with gastrointestinal conditions (e.g., inflammatory bowel disease, Crohn's disease, etc.) that may affect consumption of the treatment supplements.
  4. * Individuals with clinically important renal, hepatic, cardiac pulmonary, pancreatic, neurologic or biliary disorders; insulin-dependent and orally controlled diabetics will also be excluded from the study.
  5. * Individuals with a recent history of cancer other than non-melanoma skin cancer.
  6. * Individual's that have trouble swallowing pills.
  7. * Individuals that have participated as a subject in any other clinical study within 30 days of screening.
  8. * Individuals with a history of alcohol abuse or other substance abuse within the previous 2 years.
  9. * Individuals that currently use tobacco products including chewing tobacco and cigarettes.

Contacts and Locations

Study Contact

Mark Levy
CONTACT
801 954 7783
mark.levy@usanainc.com

Principal Investigator

Mark Levy, PhD
PRINCIPAL_INVESTIGATOR
USANA Health Sciences

Study Locations (Sites)

US Ski and Snowboard Center of Excellence
Park City, Utah, 84060
United States

Collaborators and Investigators

Sponsor: USANA Health Sciences

  • Mark Levy, PhD, PRINCIPAL_INVESTIGATOR, USANA Health Sciences

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-03-06
Study Completion Date2023-12-31

Study Record Updates

Study Start Date2023-03-06
Study Completion Date2023-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Upper Respiratory Tract Infections
  • Mental Stress